Merit Medical Systems Q3 adjusted profit beats estimates on strong product demand; raises 2026 outlook
Overview
U.S. medical device maker's Q3 revenue rose 8.4% yr/yr, with organic constant-currency revenue up 8.9%
Adjusted EPS for Q3 beat analyst expectations
Adjusted net income for Q3 beat analyst expectations
Outlook
Merit expects 2026 revenue between $1.635 bln and $1.642 bln
Company forecasts 2026 non-GAAP EPS of $4.33 to $4.37
Company expects 2026 constant-currency revenue growth of 7.0%-7.5%
Result Drivers
ORGANIC GROWTH - Co attributed results to 9% organic constant currency revenue growth, excluding impact of divestiture, per CEO Martha G. Aronson
PRODUCT DEMAND - Co said better-than-expected demand across Foundational and Therapeutic platforms drove revenue growth
THERAPEUTIC PLATFORM - Revenue rose 14% yr/yr, led by 33% growth in Endoscopy, 32% in OEM and 16% in Oncology
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Adjusted EPS | Beat | $1.12 | $1.04 (11 Analysts) |
Q3 EPS | $0.70 | ||
Q3 Adjusted Net Income | Beat | $67.40 mln | $62.79 mln (10 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Merit Medical Systems Inc is $100.00, about 8.4% above its October 28 closing price of $92.21
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 16 three months ago
Reuters Recommended Reads
Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption
Oct 29 - West Pharmaceutical tops Q3 net sales, profit expectations, raises FY guidance
Oct 28 - Boston Scientific warns of tough 2027 on China pricing, heart-device weakness
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)